Elopag 50MG (Eltrombopag)

Basic Product Information of Elopag 50MG (Eltrombopag)

How Elopag 50MG (Eltrombopag) Works: Thrombopoietin Receptor Agonism

Eltrombopag, the active ingredient in Elopag 50MG, is a selective, orally bioavailable small-molecule agonist of the thrombopoietin receptor (TPO-R), also designated c-Mpl. Thrombopoietin receptor agonist (TPO-RA) refers to a drug class that mimics or augments the action of endogenous thrombopoietin to increase platelet production from the bone marrow. Eltrombopag binds to the transmembrane domain of c-Mpl a site structurally distinct from the binding site of endogenous thrombopoietin and initiates intracellular signalling through the JAK2 and STAT pathways. This signalling cascade stimulates the proliferation, differentiation, and maturation of megakaryocyte progenitor cells, which then release platelets into the systemic circulation.

Because eltrombopag occupies a receptor site distinct from endogenous thrombopoietin, it can act additively with circulating TPO, providing platelet-stimulating activity even in patients whose own thrombopoietin levels are normal or elevated. This mechanism is therapeutically important in chronic ITP where accelerated platelet destruction outpaces bone marrow production in severe aplastic anemia (SAA), where overall bone marrow failure suppresses platelet output, and in chronic hepatitis C, where interferon-based antiviral therapy further suppresses thrombopoiesis. Clinicians building comprehensive blood disorder management programmes can review the full range of oncology and haematology medicines at Mediaid Pharmacy for companion and supportive therapies.

In the pivotal RAISE trial for chronic ITP, eltrombopag at a starting dose of 50 mg once daily titrated to response achieved a platelet response (count ≥50 × 10⁹/L) in 59% of patients versus 16% on placebo (odds ratio 9.61; p <0.0001) over 6 months. Eltrombopag at the 50 mg starting dose also significantly reduced both the rate of clinically significant bleeding events (WHO grade 2 or higher) and the requirement for rescue medication. The 50 mg dose is the reference-label standard starting dose for all non-East-Asian adults with chronic ITP, and is the strength most frequently initiated in global haematology practice outside East Asia.

Approved Indications of Eltrombopag (Reference Label for Elopag 50MG (Eltrombopag))

Eltrombopag, the active ingredient in Elopag 50MG, is approved internationally across three distinct thrombocytopenic conditions in adult and eligible paediatric patients. Prescribers in Bangladesh should confirm the exact locally approved indications on the Elopag product label before initiating therapy.

Key Clinical Benefits of Elopag 50MG (Eltrombopag)

Dosage and Administration of Elopag 50MG (Eltrombopag)

Clinical Monitoring Requirements During Elopag 50MG (Eltrombopag) Treatment

Hepatotoxicity is the most clinically significant non-haematologic risk of eltrombopag therapy. The reference label mandates liver function tests (ALT, AST, and bilirubin) at baseline, every 2 weeks during the dose-adjustment phase, and monthly once a stable dose has been established. If ALT rises to ≥3× the upper limit of normal accompanied by signs of hepatic dysfunction or hyperbilirubinemia, or reaches ≥5× the upper limit of normal on two consecutive assessments, eltrombopag must be discontinued immediately. Patients with pre-existing liver disease require more intensive monitoring from the outset.

Platelet count must be monitored weekly during treatment initiation and the dose-adjustment phase, then monthly once a stable platelet response is documented. The target platelet count for ITP is 50–200 × 10⁹/L sufficient to prevent clinically significant bleeding without generating pro-thrombotic platelet excess. Thromboembolic events including deep vein thrombosis, pulmonary embolism, and portal vein thrombosis have been reported when platelet counts were driven above the therapeutic range; the 50 mg starting dose must be titrated and not assumed to be the maintenance dose without platelet monitoring confirmation. Monthly peripheral blood smear review and complete blood count are required to detect morphological changes consistent with bone marrow fibrosis or reticulin deposition. Ophthalmic examination for cataracts is required at baseline and at regular intervals during treatment.

Drug Interactions and Important Safety Information for Elopag 50MG (Eltrombopag)

The most clinically consequential drug interaction for eltrombopag is chelation by polyvalent cations present in food and concurrent medications. Calcium in dairy products and calcium-fortified beverages, aluminum and magnesium in antacids, iron in supplements, and selenium or zinc in multivitamins all form insoluble complexes with eltrombopag in the gastrointestinal tract, reducing systemic absorption by up to 70%. Because the 50 mg dose was validated under fasting conditions in the RAISE trial, departures from the fasting administration rule can functionally reduce the dose to sub-therapeutic levels without any visible indicator for the patient. This interaction requires explicit counselling at every prescribing visit.

Eltrombopag inhibits the hepatic uptake transporters OATP1B1 and OATP1B3, increasing plasma concentrations of co-administered drugs that depend on these transporters for hepatic clearance. Co-administration with rosuvastatin increases rosuvastatin area under the curve (AUC) by approximately 55%; a rosuvastatin dose reduction is recommended and patients should be monitored for statin-associated myopathy and rhabdomyolysis. Eltrombopag is metabolised partly by CYP1A2 and CYP2C8; strong inhibitors of these enzymes including ciprofloxacin, fluvoxamine, and gemfibrozil may increase eltrombopag systemic exposure and require clinical assessment. Anticoagulants and antiplatelet agents must be used with particular caution alongside eltrombopag; the combination of drug-driven platelet elevation and antiplatelet therapy requires individualised benefit–risk assessment by the treating specialist. Patients must provide a complete medication list including over-the-counter products and herbal supplements before starting Elopag 50MG.

Side Effects and Precautions of Elopag 50MG (Eltrombopag)

Who Should Use Elopag 50MG (Eltrombopag)?

Elopag 50MG (Eltrombopag) is the standard first prescription strength for non-East-Asian adults and paediatric patients aged 6 to 17 years with chronic immune thrombocytopenic purpura (ITP) who have not achieved an adequate platelet response to corticosteroids, immunoglobulins, or splenectomy, and whose platelet count and clinical bleeding risk warrant intervention. It is also indicated for adults with severe aplastic anemia (SAA) when used as part of combination immunosuppressive therapy for treatment-naïve disease, or as monotherapy for SAA refractory to immunosuppression. The 50 mg strength aligns directly with the starting dose validated in the RAISE and NHLBI SAA trials, ensuring clinical evidence directly supports each prescription initiated at this dose level. Haematologists assess baseline liver function, platelet count, peripheral blood smear, and ophthalmic status before initiating Elopag 50MG. For patients who require complementary haematology or cancer therapies alongside eltrombopag, Mediaid Pharmacy’s oncology specialty medicines range provides a wide selection of targeted and supportive treatments available for global delivery.

Global Supplier: Mediaid Pharmacy Worldwide Shipping for Elopag 50MG (Eltrombopag)

Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping. Elopag 50MG (Eltrombopag) is available in 14’s and 28’s tablet packs, and all orders are supported by pricing quotations, stock confirmation, regulatory documentation, and end-to-end delivery tracking. Hospitals, specialist clinics, distributors, and patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries about Elopag 50MG Eltrombopag stock, pricing, and international delivery timelines. Buyers sourcing multiple haematology or oncology medicines in a single shipment can browse the complete oncology medicine collection before requesting a consolidated quotation.

Why Choose Elopag 50MG (Eltrombopag) from Mediaid Pharmacy?

Elopag 50MG (Eltrombopag) provides haematology teams with a Bangladesh-registered 50 mg eltrombopag tablet the dose strength that anchored the landmark RAISE trial (59% platelet response rate versus 16% for placebo) and the NHLBI treatment-naïve SAA Phase II trial (~94% overall haematologic response rate with combination immunosuppression). The 50 mg strength is the reference-label standard starting dose for non-East-Asian adults with chronic ITP and for paediatric patients aged 6 to 17 years, ensuring every initiated prescription is grounded in validated clinical evidence. Mediaid Pharmacy supplies Elopag 50MG in 14’s and 28’s packs with full product documentation, specialist supply support, and worldwide shipping from Dhaka. Every order begins with a prescription-based enquiry that maintains supply aligned with clinical need. To compare eltrombopag with other targeted haematology agents or to source additional oncology therapies, visit the Mediaid Pharmacy oncology medicines section and contact the team for a personalised quotation.

Frequently Asked Questions About Elopag 50MG (Eltrombopag)